CLINICAL DEVELOPMENT IN ONCOLOGY
Influx of adoptive cell therapies may be on the horizon
The most popular type of adoptive cell therapy by far is T-cell immunotherapy, specifically chimeric antigen receptor (CAR)-T cell therapy.
GLOBALDATA HEALTHCARE
Figure 1: Adoptive cell therapy trials, by status. Source: GlobalData, Pharma Intelligence Center (Accessed: May 2024). A
doptive cell therapy is a type of immunotherapy comprising cells that are engineered and expanded ex vivo
and administered to stimulate the immune system and kill tumour cells or other diseased cells. There are three main categories of adoptive cell therapies: tumour-infiltrating lymphocyte (TIL) immunotherapy, natural killer (NK) cell immunotherapy, and T-cell immunotherapy. By far the most popular type of adoptive cell therapy is T-cell immunotherapy, specifically chimeric antigen receptor (CAR)-T-cell therapy, which accounts for 55% of all adoptive cell therapy trials, according to data obtained from GlobalData’s Trials Intelligence platform. Adoptive cell therapy is still in its infancy. Additional insights from GlobalData’s Trials Intelligence platform show that around 42% of all adoptive cell therapy trials are ongoing
(Figure 1, above), indicating that there may be an upcoming influx of adoptive cell therapies in the pipeline. However, most of these trials are in early phases so there is a long road ahead to see if these promising therapies can progress to the market. Furthermore, there is a significantly high
proportion of adoptive cell therapy trials that have either been suspended, terminated, or withdrawn (Figure 1), indicating the presence of added safety and efficacy concerns associated with biological factors and the increased difficulty with advancing these therapies. Although the number of ongoing studies demonstrate some sponsors are tackling these difficulties head on, it has only been 12 years since the first paediatric patient received CAR-T therapy and seven years since the first CAR-T therapies were commercialised. Only time will determine how the landscape of adoptive cell therapy will change.
Clinical Trials in Oncology | 27
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
